Slade L, Syeda N, Mistry H D, Bone J N, Wilson M, Blackman M, Poston L, Godfrey K M, von Dadelszen P, Magee L A
Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia.
Department of Obstetrics and Gynaecology, Women's and Children's Hospital, Adelaide, SA, Australia.
Int J Obes (Lond). 2025 Jun 16. doi: 10.1038/s41366-025-01803-8.
Obesity is a major risk-factor for adverse pregnancy outcomes. While the 2017 American College of Cardiology/American Heart Association (ACC/AHA) classification of normal and abnormal blood pressure (BP) outside pregnancy has been suggested for use in pregnancy, the impact on adverse outcomes has not been examined specifically in women with obesity.
The UK Pregnancies Better Eating and Activity Trial (UPBEAT) enroled women with a body mass index (BMI) ≥ 30 kg/m. In secondary analyses, maximal antenatal BP was categorised by 2017 ACC/AHA criteria: 'Normal' BP (systolic [sBP] <120 mmHg and diastolic [dBP] <80 mmHg), 'Elevated' BP (sBP 120-129 mmHg and dBP <80 mmHg), 'Stage 1 hypertension' (sBP 130-139 mmHg and/or dBP 80-89 mmHg), and 'Stage 2 hypertension' (sBP ≥140 mmHg and/or dBP ≥90 mmHg, non-severe [sBP 140-159 mmHg and/or dBP 90-109 mmHg] and severe (sBP ≥160 mmHg and/or dBP ≥110 mmHg). Main outcomes were preterm birth, postpartum haemorrhage (PPH), birthweight <10th centile (small-for-gestational age, SGA), and neonatal intensive care unit (NICU) admission. Associations with adverse outcomes were adjusted for UPBEAT intervention, maternal age, booking BMI, ethnicity, parity, smoking, alcohol, and previous pre-eclampsia or gestational diabetes. Diagnostic test properties (positive and negative likelihood ratios, -LR and +LR) were assessed as individual categories (vs. 'Normal' BP), and as threshold values.
Severe 'Stage 2 hypertension' (vs. BP < 160/110 mmHg) was associated with PPH (RR 2.57 (1.35, 4.86)) and SGA (RR 2.52 (1.05, 6.07)) only in unadjusted analyses. No outcomes were associated with 'Stage 1 hypertension' or 'Elevated BP'. All +LR were <5.0 and -LR ≥ 0.20, indicating that no BP threshold was useful as a diagnostic test to detect preterm birth, PPH, SGA, or NICU admission.
Among pregnant women with obesity, we found no evidence that lowering the antenatal BP considered to be abnormal (from 140/90 mmHg) would assist in identifying women and babies at risk.
肥胖是不良妊娠结局的主要风险因素。虽然有人建议将2017年美国心脏病学会/美国心脏协会(ACC/AHA)对非孕期正常和异常血压(BP)的分类用于孕期,但尚未专门研究其对肥胖女性不良结局的影响。
英国孕期更佳饮食与活动试验(UPBEAT)纳入了体重指数(BMI)≥30kg/m²的女性。在二次分析中,根据2017年ACC/AHA标准对产前最高血压进行分类:“正常”血压(收缩压[sBP]<120mmHg且舒张压[dBP]<80mmHg)、“血压升高”(sBP 120 - 129mmHg且dBP<80mmHg)、“1期高血压”(sBP 130 - 139mmHg和/或dBP 80 - 89mmHg)以及“2期高血压”(sBP≥140mmHg和/或dBP≥90mmHg,非重度[sBP 140 - 159mmHg和/或dBP 90 - 109mmHg]和重度[sBP≥160mmHg和/或dBP≥110mmHg])。主要结局包括早产、产后出血(PPH)、出生体重低于第10百分位数(小于胎龄儿,SGA)以及新生儿重症监护病房(NICU)收治。对不良结局的相关性进行了调整,以考虑UPBEAT干预、产妇年龄、登记时的BMI、种族、产次、吸烟、饮酒以及既往子痫前期或妊娠期糖尿病情况。评估了诊断试验特性(阳性和阴性似然比,-LR和+LR)作为个体类别(与“正常”血压相比)以及作为阈值。
仅在未调整分析中,重度“2期高血压”(与血压<160/110mmHg相比)与PPH(RR 2.57[1.35, 4.86])和SGA(RR 2.52[1.05, 6.07])相关。没有结局与“1期高血压”或“血压升高”相关。所有+LR均<5.0且-LR≥0.20,表明没有血压阈值可作为检测早产、PPH、SGA或NICU收治的诊断试验。
在肥胖孕妇中,我们没有发现证据表明降低被认为异常的产前血压(从140/90mmHg起)有助于识别有风险的妇女和婴儿。